Downloading...
Download

Moderna

Moderna about to reclaim bullish Channel. Short-Term-BULLISH! Not financial advice! With the new corona variant spreading fear all over the world, PFE and MRNA are running. I think it's possible for MRNA to reclaim the bullish channel, aka the Bull-Trap that broke down, when PFE announced the Paxlovid-med. I got in MRNA way to late, now taking a risky trade, since MRNA gaps like crazy, and there's always the chance that it'll brake down to be traded at skipped price-levels. I think one should watch out for PFE announcing Paxlovid being effective against the omicron variant, which could lead a lot of investors to switch to PFE. Today I want to see MRNA reclaiming the bullish channel at $377,xx and hold within this channel. From there on, it's more than a 30% ride to the top of the channel. But this stock has done crazy things like this in the past. Depending on how fast MRNA manages to reclaim the top, the price correlates with the last ATH at $494,xx. I think, if it manages to get back at the center of the channel, it will be rejected at the old resistance at $463,xx first, settle a bit and then trying to break the $500. My plan is to sell at $463 and then watch how things develop. But remember if, you're not in it by now, it maybe is bad timing to get in at this pricelevel. Risk is way to high, because of the gaps. That is why I marked this trading strategy as Neutral. Good luck in the markets! Again, this is not financial advice!
NASDAQ:MRNA
by robvanhoven
Are Pfizer, Merck and Moderna Still Worthy to Be in Portfolio?Pfizer is now outperforming Merck and Moderna stocks after announcing its anti-COVID pill despite its shares not being the best option for investments in the first half of this year. Pfizer stocks gained only 35% since the beginning of this year until mid-August. Moderna stocks were skyrocketed by 375% for the same period. So, undoubtedly Moderna was the favourite. However, when Merck announced the production of its COVID pills, the shares of vaccine producers spiraled into correction. But Merck was not the one to get its COVID pills into the market. Its shares peaked up to $91.40 and plunged with a gap after Pfizer announced its even more promising COVID treatment pills. The company said clinical trials showed that hospitalisation and deaths were reduced by 89% when the pill is taken within three days of the onset of symptoms.  So, this news from Pfizer came on November 5 and since then the technical picture for the above-mentioned three Big Pharma stocks changed dramatically. Pfizer shares are taking the lead while waving away all their August corrections and now they are close to the all-time highs at $51.86. If they are successful at breaking through this level, technical price acceleration may bring its stocks to $56.03 and $58.60 may be the next target. These levels could be a correction impulse to the decline from $51.86 to $40.94 per share. The nearest support level is at $47.70-48.80. As for Moderna stocks, the last quarter financial report hit them badly. Nevertheless, impulsive selloffs are now over as shares dipped to the important support level established in November 2020. So, now it is worth consider buying these shares. Corrections went into an ABC zigzag and shares are likely to return on the upside track. Initially, A and B waves were suggested to be equal, but now we see that the C wave is 161.8% of the A wave that gave us a decline to $225.85 per share. In my opinion Moderna shares have accomplished their correction and are close to the trend line of the last 12 month, and for that reason are an interesting investment. So, Moderna stocks may even be catching up to Pfizer. The nearest targets for Moderna stocks are within the area of $283-291 where EMA 21 moving average is located at the daily timeframe chart together with the resistance level formed by dips of July and October 2021. Moreover, at the $298 landmark, the resistance line of the downward trend that started on September 23 is located. If this zone would be broken the perspectives for Moderna stocks should be extended.Despite all these different technical pictures for these stocks, I would recommend holding all three stocks in your investment portfolio. Pfizer and Merck continue to compete in the COVID pills market while Moderna has a forward P/E ratio at 9, which highlights that the company is the cheapest among the Big Pharma biotech companies if compared with its peers sector performance.
NASDAQ:MRNALong
by scavoanastasiia
Moderna (MRNA) Swing Trade IdeaModerna broke trend to the downside, so long term view is more likely a short rather than long. As illustrated in the chart, I wouldn't short at current prices, but around the red level I have drawn. The trade is invalidated if it closes above the red zone with high volume. If it closes above it but on low volume, it could be a fake out with the following candles closing below it once again. The red zone at the very top is the next resistance zone if it does get through the first resistance zone. Please disregard the overall timeframe estimate, it can take longer or shorter for this trade to play out, but the move is the general idea.
NASDAQ:MRNAShort
by wallstreetnomad
3
Moderna sliding back to Earth. MRNAPivot on a huge impulse fractal confirmed. We are drawing more and more zigzags from now on. Our goals are shown. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
NASDAQ:MRNAShort
by Rykin_Capital
What May Happen to Moderna and Pfizer?International pharmaceutical giant Merck & Co announced the successful end of its clinical trial of the world’s first oral COVID-19 antiviral drug molnupiravir in the simple form of a pill. The company has claimed that molnupiravir effectively decreases the risk of hospitalization and death of sick individuals who have just contracted the virus or have advanced symptoms by half.  Moreover, the company also suggested that molnupiravir could be used to prevent the contraction of  the coronavirus. But what is most important at this stage is that fact that the clinical trials of molnupiravir showed high effectiveness against different COVID-19 variants, including the terrifying Delta variant. This seems to be good news for antivaxers or for anybody who is looking for an alternative prevention method from COVID-19 other than the vaccine.  Whether you agree or disagree with having the vaccine, it is worthwhile to consider this information as a means of expanding your investment portfolio with Merck stocks. Additionally, COVID-19 major vaccine producers Pfizer and Moderna stocks may suffer if the new pill is officially registered. Let’s take a look at Pfizer and Moderna’s price charts. Both stocks suffered a 50% correction from their peaks in August. Although, Pfizer business model is more diversified than that of Moderna’s, the technical picture shows that the upward trend for Pfizer stocks is more in danger. The reason for such fears is that over the last three consecutive trading sessions its stocks closed below the trend support line that started in February 2021. So, if Pfizer stock prices fail to recover above the $43.20-44 correction, they are likely to continue towards the $38.20-39.20 area. In this area, two important technical lines cross – one is the support line of the upward trend that started in March 2020 and the second – former resistance line that connects September 2020 and May, June 2021 highs. Pfizer and BioNTEch may have a trump of positive opinion by the Committee for Medicinal Products for Human Use (CHMP) for the administration of the Pfizer-BioNTech COVID-19 vaccine as a booster shot six months after the second dose, but this factor is already priced in. The Moderna stock prices chart seems to be more complex as it shows that the March 2020 long-term upward trend is supported by the upward trend that started in May 2021 in the area of $319-321. Even the correction from the peak of $496.71 closely echoes the ABC correction structure, where A and C waves are equal. And if so, Moderna stocks may recover both not only to recent highs, but to new all-time highs. Such a scenario might be activated if prices hold above the downward channel from August 10. In this case new targets may open at $563-565. Technical perspectives of Merck stocks will be reviewed in the coming comments.
NASDAQ:MRNALong
by scavoanastasiia
4
MODERNA POSSIBLE DISTRIBUTION!Hello my beauties. I think MRNA has entered a distribution range, as the ST (second test) seemed to be pretty weak, and the price is now showing weakness below the trading range. We are going to wait for further developments in price action and eventually take a trade on the final LPSY. For those of you who like trading ranges, this might be a juicy opportunity. Watch for the creation of an UT (upthrust) and an UTAD (upthrust after distribution) before you take your trade. If you find this idea to be helpful like, follow, and drop a comment below if you'd want me to analyse a different pair. Consider supporting me if you think I am providing you with value. Peace. Luca, TrickleDownFX
NASDAQ:MRNAShort
by TrickleDownFX
3
MRNA Daily TimeframeSNIPER STRATEGY (new version) It works ALMOST ON ANY CHART. It produces Weak, Medium and Strong signals based on consisting elements. NOT ALL TARGETS CAN BE ACHIEVED, let's make that clear. TARGETS OR ENTRY PRICES ARE STRONG SUPPORT AND RESISTANCE LEVELS. ENTRY PRICE BLACK COLOR TARGETS GREEN COLOR STOP LOSS RED COLOR DO NOT USE THIS STROTEGY FOR LEVERAGED TRADING. It will not give you the whole wave like any other strategy out there but it will give you a huge part of the wave. The BEST TIMEFRAMES for this strategy are Daily, Weekly and Monthly however it can work on any timeframe. Consider those points and you will have a huge advantage in the market. There is a lot more about this strategy. It can predict possible target and also give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts. START BELIEVING AND GOOD LUCK HADIMOZAYAN
NASDAQ:MRNAShort
by hadimozayan
MODERNA Daily TimeframeSNIPER STRATEGY This magical strategy works like a clock on almost any charts Although I have to say it can’t predict pullbacks, so I do not suggest this strategy for leverage trading. It will not give you the whole wave like any other strategy out there but it will give you huge part of the wave. The best timeframe for this strategy is Daily, Weekly and Monthly however it can work any timeframe above three minutes. Start believing in this strategy because it will reward believers with huge profit. There is a lot more about this strategy. It can predict and also it can give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts.
NASDAQ:MRNAShort
by hadimozayan
4
Moderna getting ready for a move higher, Maybe $500+ level(s)Ive been watching the recent uptick figuring there would be a place to sneak in and ride it down to ride back up even higher than it just moved since I missed that ride. She fell rite to my line and held rite around it. Personally i think the $386 level is in play but only if it continues down under $410. once it taps that line or the bottom of the triangle once maybe twice I believe it will make a new ATH over $500. I added some extras levels for reference.
NASDAQ:MRNAShort
by ahancovsky
$MRNA: a fine cup of coffee!After Pfiser's booster shot approval this month, $MRNA will surely follow. Today, they announced a combined flu and COVID shot, as well as signing a multi-year deal with a manufacturer, National Risilience Inc, which will help reach its 2021 goal of delivering 800M-1B doses of its vaccine. This has got the stock soaring and the rim of the cup is forming as you can see in my beautiful drawings. At least that's what my mom calls them. So, get ready for a pullback and then a trip to the moon! 😉🚀🚀🚀
NASDAQ:MRNALong
by alxiv
5
Moderna is choosing the ascending channelIt is not a prediction. This stock has chosen its channel (BULLISH). What's your opinion about $MRNA? What's your PT? Your comments are welcome. ############## Take into account that fundamentals (news) supplement technical analysis . A trader does not use a crystal ball to predict the future (news and people's reactions). Additionally technical analysis is not an exact science. It involves a degree of subjectivity. Legal disclaimer: I am not a financial advisor. The advice here given is not a financial advice even though my excitement might make it look like such. This account shouldn't be followed by anyone expecting something from me. You trade at your own risk and nobody can guarantee you results. Even if someone could, I don't.
NASDAQ:MRNALong
by ymarkets